The detection of circulating tumor DNA (ctDNA) in the bloodstream following surgery for patients with liver metastases may provide crucial information regarding the necessity of further treatment. New research, presented at the ESMO 2026 Congress, suggests that routine blood analysis can help stratify risk, allowing clinicians to determine which patients are most likely to benefit from adjuvant chemotherapy—treatment administered after the initial surgery. Colorectal cancer (CRC) originates in the large intestine or rectum.
The progression typically begins with minor changes in the intestinal lining, such as polyps, which can, over time, develop into malignant tumors. In advanced stages, the cancer can spread to other organs, necessitating monitoring for residual disease. The study focused on leveraging ctDNA to refine treatment protocols for these complex cases.
By analyzing the DNA fragments circulating in the blood, researchers aim to identify molecular signatures that predict residual cancer activity. This capability moves treatment decisions away from a one-size-fits-all approach toward highly personalized medicine. The primary goal of this diagnostic tool is to reduce the incidence of overtreatment.
Currently, adjuvant chemotherapy is often administered broadly, but the ability to predict response could prevent unnecessary exposure to chemotherapy agents for patients who might not clinically benefit from the therapy, while ensuring that those most at risk receive timely intervention. This represents a significant step toward optimizing care pathways for patients with advanced gastrointestinal malignancies.
Topics: #which #patients #benefit
